Table 1—

Effect of 4-week treatment with placebo or NVP DPP728 at 100 mg t.i.d. or 150 mg b.i.d. in subjects with type 2 diabetes on body weight, fasting and prandial glucose, and insulin and lipid levelslegend

Placebo (n = 32)NVP DPP728
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 30)
Body weight (kg)Baseline82.6 ± 2.479.9 ± 2.077.9 ± 2.0
Change−0.2 ± 0.30.1 ± 0.3−0.1 ± 0.3
24-h plasma glucose (mmol/l)Baseline9.2 ± 0.38.9 ± 0.38.8 ± 0.3
Change−0.1 ± 0.1−1.1 ± 0.1*−1.0 ± 0.1*
24-h plasma insulin (pmol/l)Baseline157 ± 12157 ± 13153 ± 15
Change16 ± 8−9 ± 8−9 ± 8
FPG (mmol/l)Baseline8.7 ± 0.28.5 ± 0.38.5 ± 0.3
Change0.1 ± 0.2−0.9 ± 0.2*−0.6 ± 0.2
Glucose excursion§ (mmol/l)Baseline4.1 ± 0.33.9 ± 0.24.1 ± 0.3
Change−0.1 ± 0.2−1.2 ± 0.2*−1.3 ± 0.2*
Prandial glucose (mmol/l per h)Baseline6.0 ± 0.84.8 ± 0.75.5 ± 0.7
Change−0.0 ± 0.6−2.8 ± 0.6*−3.0 ± 0.6*
Fasting insulin (pmol/l)Baseline79 ± 681 ± 878 ± 7
Change4 ± 5−1 ± 55 ± 0
Insulin-to-glucose excursion rate (pmol/mmol)Baseline12.6 ± 0.916.2 ± 1.715.9 ± 2.8
Change1.7 ± 0.83.6 ± 2.07.4 ± 2.1
Total cholesterol (mmol/l)Baseline5.8 ± 1.05.7 ± 0.85.5 ± 0.9
Change0.1 ± 0.1−0.2 ± 0.17−0.2 ± 0.1
HDL cholesterol (mmol/l)Baseline1.3 ± 0.51.3 ± 0.31.3 ± 0.3
Change0.01 ± 0.030.03 ± 0.030.02 ± 0.03
LDL cholesterol (mmol/l)Baseline3.7 ± 0.93.6 ± 0.83.5 ± 0.8
Change0.02 ± 0.09−0.17 ± 0.08−0.18 ± 0.09
VLDL cholesterol (mmol/l)Baseline0.35 ± 0.150.32 ± 0.160.32 ± 0.14
Change0.03 ± 0.02−0.02 ± 0.02−0.01 ± 0.02
Triglycerides (mmol/l)Baseline1.7 ± 0.71.7 ± 1.11.6 ± 0.7
Change0.14 ± 0.09−0.14 ± 0.09−0.09 ± 0.09
  • legend

    legend Data are means ± SEM.

  • *

    * P < 0.001;

  • P < 0.05 versus placebo;

  • P < 0.05;

  • §

    § glucose excursion = difference between maximum glucose in the 4-h postbreakfast period minus mean of prebreakfast glucose;

  • prandial glucose = area under the 4-h plasma glucose curve after breakfast;

  • peak Δ postprandial insulin divided by peak Δ postprandial glucose after breakfast.